The Trends for 2022

Jennifer Friel Goldstein, Managing Partner, Silicon Valley Bank

Jennifer Friel Goldstein is the Managing Partner for Life Science & Healthcare at SVB Capital and a founding member of VentureForward, a non-profit working to develop a diverse, equitable and inclusive venture ecosystem. She is also an advisory board member of SpringBoard Enterprises and the Women’s Health Innovation Coalition. A bioengineer by training, Jennifer has more than 20 years of experience in the venture and startup market segments, including leading and building SVB’s Healthcare franchise over the decade. Prior to that, she was a director on Pfizer's Venture Capital team, where she developed investments into several life sciences companies and independently managed Pfizer’s $250 million private equity portfolio. Jennifer has also served as a consultant on private equity deals across Europe while at Bain & Company and has held operational and research roles at Chiron, Genelabs, and Genencor.   Jennifer graduated magna cum laude with a BSE in Bioengineering and a Master's of Biotechnology from the University of Pennsylvania. She holds an MBA from the Wharton School, where she was named a Joseph Wharton Fellow.  She also serves as a director at Alexandria Real Estate Equities, Inc. Jennifer lives in the Bay Area with her husband and their twin children. 

Tom Burt, Partner, Sofinnova Crossover

Tom joined Sofinnova in June 2017 and brings experience of life science investment banking and late-stage public/private investing. Tom joined from Peel Hunt, a London-based growth investment bank, where he was Senior Healthcare research analyst. Prior to this he was an Investment Director with Ares Life Sciences, a late-stage healthcare fund with c.€2bn AuM and backed by the Bertarelli (Serono) Family. Before this he was based at Novo Growth Equity, an investment division of Novo Holdings, responsible for investing US$200m per year in late-stage public/private life science companies in US & Europe. Tom began his finance career in 2006 as member of Piper Sandler’s European Healthcare Investment Banking team working on financings and M&A for late-stage European life science companies. Previously, Tom worked at GSK in large-scale vaccine manufacture and holds an Engineering Doctorate and Master’s degree in Biochemical Engineering. ​

Neil Shah, Head of content, Edison Group

Neil is a qualified accountant (PwC) with nine years’ experience as an equities analyst at Goldman Sachs. As Goldman’s building and materials analyst in London, he was ranked second by both Institutional Investor and Reuters. He left Goldman Sachs to help set up the specialist trading hedge fund, Tusker Capital.

Gareth Powell, Head of healthcare, Polar Capital

Gareth joined Polar Capital in 2007 to set up the Healthcare team. Prior to Polar Capital, Gareth worked at Framlington, where he began his career in investment management in 1999. Soon afterwards, he joined the Healthcare Team in 2001 and helped launch the Framlington Biotech Fund, which he managed from 2004 until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas). As well as this, Gareth worked for the Oxford Business School and various academic laboratories including the Sir William Dunn School of Pathology and the Wolfson Institute for Biomedical Research.